Competitive Technologies (OTCMKTS:CTTC) and Veracyte (NASDAQ:VCYT) Critical Comparison

Veracyte (NASDAQ:VCYT) and Competitive Technologies (OTCMKTS:CTTC) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, dividends, institutional ownership, risk and earnings.

Earnings & Valuation

This table compares Veracyte and Competitive Technologies”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veracyte	$445.76 million	7.58	$24.14 million	$0.38	112.51
Competitive Technologies	N/A	N/A	N/A	N/A	N/A

Veracyte has higher revenue and earnings than Competitive Technologies.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Veracyte and Competitive Technologies, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veracyte	1	2	5	1	2.67
Competitive Technologies	0	0	0	0	0.00

Veracyte currently has a consensus target price of $46.14, indicating a potential upside of 7.92%. Given Veracyte’s stronger consensus rating and higher probable upside, equities analysts plainly believe Veracyte is more favorable than Competitive Technologies.

Profitability

This table compares Veracyte and Competitive Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Veracyte	6.12%	7.23%	6.58%
Competitive Technologies	N/A	N/A	N/A

Summary

Veracyte beats Competitive Technologies on 8 of the 8 factors compared between the two stocks.

About Veracyte

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm’s portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.

About Competitive Technologies

Calmare Therapeutics Incorporated, a medical device company, develops and commercializes products and technologies for chronic neuropathic pain and wound care affliction patients in the United States. Its flagship medical device is Calmare Pain Therapy Device, a non-invasive and non-addictive modality for the treatment of chronic and neuropathic pain. The company was formerly known as Competitive Technologies, Inc. and changed its name to Calmare Therapeutics Incorporated in August 2014. Calmare Therapeutics Incorporated was founded in 1968 and is based in Fairfield, Connecticut.